Highlights
Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’).
Histology-based therapy is important to ...
Login
Sign Up FREE
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Register now for FREE Access
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.